Newell Brands (NWL), a household product supplier, and Teva Pharmaceuticals (TEVA) are value stocks. Both stocks trade at discounts because investors doubt they have good prospects ahead. Investors may buy these stocks at a low price. The better deal depends on the recovery prospects.
Newell posted non-GAAP earnings of 16 cents a share. For the full year 2023, net sales of $8.6 billion are below the $9.09 billion analyst consensus. In the last three years, the company reduced inefficiencies from its operational fragmentation. To capture growth internationally, it needed to unify its supply chain.
NWL stock is a worthwhile consideration as the company optimizes its product categories and lowers inventory.
In the generic drug sector, Teva posted a 4.9% decline Y/Y in revenue of $3.9 billion. For 2023, it will earn $2.25 to $2.55 a share. The Q4 results suggest the business is stabilizing. The firm must cut its debt since interest payments are costing nearly $1 billion annually.
Teva has many new biosimilars, such as Humira, Stelara, and Lucentis. Investors could bet on growth recovering in the second half of 2023.
Consider both TEVA and NWL stock. They trade at a good value.
